Roche and Medivir begin hepatitis C research

Swiss pharmaceuticals companies Roche Holding AG and Medivir AB are to amend their existing HIV collaboration and begin a joint research program into hepatitis C, it was announced in a joint press release.

Medivir assumes full responsibility for the MV026048 compound being tested against HIV, with Roche continuing to participate in a guidance capacity.

Roche maintains an opt-in right, and if that occurs, future payments to Medivir will be discussed.

Medivir and Roche will try to find new compounds in hepatitis, and Medivir will have the rights to market these products in the Nordic countries. Roche will make milestones and royalty payments on Medivir's behalf.